What Is The Function Of Cardiac Valves And Their Critical Role In Heart Health

Published

Table of Contents

The cardiac valves serve as precision-engineered gatekeepers within the heart, regulating blood flow with unparalleled efficiency to sustain circulatory function. Positioned strategically between chambers and major vessels, these four specialized structures—tricuspid, pulmonary, mitral, and aortic—orchestrate a seamless sequence of opening and closing during each cardiac cycle. Their anatomical intricacy, from leaflet composition to pressure-sensitive mechanics, ensures unidirectional flow while preventing catastrophic backflow or obstructive stenosis. Dysfunction in even one valve disrupts the delicate hemodynamic balance, triggering cascading effects from reduced cardiac output to systemic organ failure.

Understanding their physiological dynamics reveals a masterclass in biomechanical synchronization, where atrial contractions, ventricular pressures, and valvular timing converge to maintain life-sustaining perfusion. Advances in diagnostic imaging and interventional cardiology have transformed valvular pathology from a terminal prognosis into a manageable condition, yet the foundational role of these valves remains indispensable. From the microscopic choreography of chordae tendineae to the macroscopic consequences of rheumatic heart disease, the cardiac valves exemplify nature’s fusion of structural ingenuity and functional precision.

what is the function of the cardiac valve

Anatomical Overview of Cardiac Valves

The cardiac valves are critical components of the heart’s functional architecture, ensuring unidirectional blood flow through the four chambers and maintaining efficient circulation. Structurally and functionally distinct, each valve operates within precise pressure gradients to prevent backflow, thereby sustaining systemic and pulmonary perfusion. Their anatomical design—comprising leaflets, fibrous annuli, chordae tendineae, and papillary muscles—directly influences their mechanical efficiency and susceptibility to pathological alterations.

The four primary cardiac valves—tricuspid, pulmonary, mitral, and aortic—are strategically positioned at the junctions between atria and ventricles, as well as between ventricles and major arteries. Their structural composition enables synchronized opening and closure in response to ventricular contraction and relaxation, optimizing cardiac output while minimizing energy expenditure.

Structural and Functional Correlation of Cardiac Valves

The anatomical features of each cardiac valve are intricately linked to its physiological role. Pressure gradients drive valve dynamics, where differences in chamber pressures determine valve opening or closure. Unidirectional flow is maintained through the coordinated action of leaflets, which act as passive flaps, and supporting structures like chordae tendineae and papillary muscles, which prevent prolapse during high-pressure phases. Below is a comparative analysis of the four valves, highlighting their positional, structural, and functional attributes.

Positional and Structural Characteristics of Cardiac Valves

The following table summarizes the anatomical and functional distinctions among the tricuspid, pulmonary, mitral, and aortic valves, emphasizing how their design facilitates specialized roles in cardiac hemodynamics.
Valve Name Position Structural Features Functional Role
Tricuspid Valve Located between the right atrium and right ventricle. Comprises three leaflets (anterior, posterior, septal).
  • Three leaflets attached to a fibrous annulus.
  • Chordae tendineae connect leaflets to papillary muscles (anterior, posterior, septal).
  • Annulus fibrosus provides structural support and aligns with ventricular contraction.
Facilitates unidirectional blood flow from the right atrium to the right ventricle during ventricular diastole. Closes during ventricular systole to prevent regurgitation into the atrium, maintaining a right atrial-right ventricular pressure gradient (≤5 mmHg during normal function).
Pulmonary Valve Situated between the right ventricle and pulmonary artery. Comprises three semilunar leaflets.
  • Three crescent-shaped semilunar cusps (right, left, anterior).
  • Lacks chordae tendineae; supported by the arterial wall and fibrous continuity with the aortic root.
  • Dilator muscles (in some species) may assist in cusp alignment.
Opens during ventricular systole to eject blood into the pulmonary artery, overcoming a right ventricular-pulmonary arterial pressure gradient (~25/10 mmHg). Closes passively during diastole to prevent backflow into the ventricle, relying on the elastic recoil of the pulmonary artery.
Mitral Valve Positioned between the left atrium and left ventricle. Comprises two leaflets (anterior and posterior).
  • Two leaflets (anterior larger, posterior smaller) with scalloped edges.
  • Chordae tendineae attach to two papillary muscles (anterolateral and posteromedial).
  • Annulus fibrosus is elliptical, aligning with left ventricular geometry.
Ensures unidirectional flow from the left atrium to the left ventricle during diastole. Closes during systole to withstand higher left ventricular-left atrial pressure gradients (up to 120 mmHg), preventing regurgitation via tension in chordae tendineae and papillary muscle contraction.
Aortic Valve Located between the left ventricle and aorta. Comprises three semilunar cusps (right-coronary, left-coronary, non-coronary).
  • Three semilunar cusps with noduli and lunulae (thickened edges).
  • Supported by the aortic root and sinuses of Valsalva (prevents prolapse).
  • Lacks chordae tendineae; closure relies on arterial pressure and cusp coaptation.
Opens during ventricular systole to eject blood into the aorta, overcoming a left ventricular-aortic pressure gradient (up to 120/80 mmHg). Closes during diastole to prevent diastolic regurgitation, maintained by the elastic recoil of the aorta and coronary artery perfusion pressure.

Mechanical Synchronization and Pathophysiological Implications

The functional integrity of cardiac valves depends on the precise timing of ventricular contraction and relaxation, which generates the necessary pressure gradients for valve operation. During ventricular systole, the tricuspid and mitral valves close to prevent backflow into the atria, while the pulmonary and aortic valves open to eject blood into their respective arteries. Conversely, during diastole, the semilunar valves close, and the atrioventricular (AV) valves open to allow passive filling.

Structural abnormalities—such as leaflet prolapse (e.g., mitral valve prolapse), calcification (e.g., aortic stenosis), or annular dilation (e.g., tricuspid regurgitation)—disrupt these pressure dynamics. For instance:

  • Mitral stenosis reduces left atrial emptying, increasing left atrial pressure and risk of atrial fibrillation.
  • Aortic regurgitation causes diastolic volume overload, leading to left ventricular eccentric hypertrophy.
  • Tricuspid regurgitation impairs right ventricular efficiency, contributing to systemic congestion.

    • The interplay between valve anatomy and hemodynamics underscores their role in maintaining cardiac efficiency. Disruptions in leaflet coaptation, chordae tendineae tension, or annular support directly correlate with valvular disorders, emphasizing the need for precise anatomical and functional alignment in both health and disease.

    Physiological Functions and Mechanical Dynamics of Cardiac Valves

    Cardiac valves serve as critical regulators of blood flow within the heart, ensuring efficient circulation through precise mechanical coordination between pressure gradients, muscle contractions, and structural integrity. Their primary role is to maintain unidirectional flow during systole and diastole, preventing pathological conditions such as regurgitation or stenosis, which disrupt cardiac efficiency and systemic perfusion. The mechanical dynamics of valve operation are intricately linked to intraventricular pressure changes, atrial-ventricular synchronization, and the elastic properties of valve leaflets and chordae tendineae.

    The following sections dissect the step-by-step hemodynamic processes governing valve function, contrasting normal physiology with dysfunctional states to illustrate the consequences of valvular disorders.

    Primary Function: Unidirectional Blood Flow and Pressure Regulation

    The cardiac cycle relies on four valves—aortic (AO), pulmonary (PU), mitral (MV), and tricuspid (TV)—to sequentially direct blood through the heart without backflow. During systole, ventricular contraction generates high-pressure gradients that force the AO and PU valves open, expelling blood into the aorta and pulmonary artery, respectively. Simultaneously, the MV and TV valves close to prevent retrograde flow into the atria. In diastole, ventricular relaxation reduces intraventricular pressure, causing the AO and PU valves to close and the MV and TV valves to open, facilitating atrial-to-ventricular filling.

    Pressure gradients are the primary drivers of valve mechanics. For example:

  • Aortic valve opening occurs when left ventricular pressure (LVP) exceeds aortic pressure (AoP) by ~5–10 mmHg.
  • Mitral valve closure is triggered when LVP surpasses left atrial pressure (LAP) during isovolumetric contraction.
    • Disruptions in these gradients—such as hypertension (elevated AoP) or ventricular hypertrophy (reduced compliance)—can impair valve function, leading to systolic dysfunction or diastolic filling defects.

    Mechanical Process of Valve Opening and Closing During the Cardiac Cycle

    The sequential activation of valves follows a pressure-volume loop governed by electrical and mechanical events. Below is a phased breakdown of valve dynamics, aligned with the cardiac cycle phases:

    Phase 1: Ventricular Filling (Diastole)

    1. Mitral and Tricuspid Valve Opening:
    2. Ventricular relaxation reduces LVP/LVP below atrial pressure (RAP/LAP), creating a pressure gradient (~5 mmHg).
    3. The MV and TV valves open passively, allowing blood to flow from atria to ventricles (~70% of filling occurs via rapid early diastole).
    4. Atrial contraction (atrial kick) contributes an additional 20–30% of ventricular filling, critical in maintaining cardiac output during tachycardia or reduced ventricular compliance.
    5. Aortic and Pulmonary Valve Closure:
    6. As ventricles relax, AoP/PaP exceeds LVP/RVP, causing the AO and PU valves to snap shut via ventricular-arterial pressure reversal.
    7. The second heart sound (S2) marks this closure, with a split audible in physiologic splitting (inspiration) due to delayed pulmonary valve closure.

    Phase 2: Isovolumetric Contraction (Early Systole)

    1. Mitral and Tricuspid Valve Closure:
    2. LVP/RVP rises above LAP/RAP (~80 mmHg in left ventricle), forcing the MV and TV valves closed to prevent regurgitation.
    3. The first heart sound (S1) is generated, with loudness influenced by valve mobility (e.g., mitral stenosis) and ventricular compliance.
    4. Pressure Buildup:
    5. Ventricular contraction increases pressure without volume change (isovolumetric phase) until LVP exceeds AoP (~120 mmHg), triggering aortic valve ejection.

    Phase 3: Ejection (Systole)

    1. Aortic and Pulmonary Valve Opening:
    2. AO/PU valves open when LVP/RVP surpasses AoP/PaP, allowing ~70% of stroke volume to be ejected during rapid ejection phase.
    3. Valvular coaptation (leaflet approximation) ensures a tight seal, preventing paravalvular leaks.
    4. Reduced Ejection Phase:
    5. As ventricular pressure declines, ejection slows, and the AO/PU valves begin to close in anticipation of diastole.

    Phase 4: Isovolumetric Relaxation (Late Systole)

    1. Aortic and Pulmonary Valve Closure:
    2. AO/PU valves close when AoP/PaP exceeds LVP/RVP, marking the end of systole.
    3. Dicrotic notch appears in aortic pressure waveforms, reflecting valve closure.
    4. Pressure Equalization:
    5. Ventricular pressure drops without volume change until LVP/LVP falls below LAP/RAP, reopening the MV/TV valves for diastole.

    Comparison: Normal Valve Function vs. Valvular Dysfunction

    The integrity of cardiac valves is essential for maintaining cardiac efficiency and systemic perfusion. Dysfunctional valves disrupt these processes, leading to compensatory mechanisms and progressive heart failure. Below is a comparative analysis of normal physiology versus pathological states:

    what is the function of the cardiac valve - Ilustrasi 2

    Clinical Significance and Pathological Conditions of Cardiac Valves

    Cardiac valve dysfunction represents a critical subset of cardiovascular diseases, significantly impairing hemodynamic efficiency and contributing to morbidity and mortality worldwide. Pathological alterations—ranging from structural degeneration to inflammatory damage—disrupt the precise synchronization of valve opening and closure, leading to compensatory mechanisms that often exacerbate cardiac workload. These conditions frequently manifest with progressive symptoms that correlate with the specific valve affected, necessitating early diagnosis to prevent irreversible cardiac remodeling. Below, structured analyses of common valvular pathologies, their etiologies, and hemodynamic consequences are presented to elucidate their clinical relevance.

    Common Pathological Conditions Affecting Cardiac Valves

    Cardiac valves are susceptible to a spectrum of intrinsic and extrinsic pathological processes, categorized primarily by their underlying mechanisms: inflammatory, degenerative, congenital, or iatrogenic. Rheumatic heart disease, once dominant in low-resource settings, remains a leading cause of valvular dysfunction in regions with limited access to antibiotics, while calcific aortic stenosis and mitral valve prolapse are increasingly prevalent in aging populations. Infectious endocarditis, though less common, carries high mortality if untreated, underscoring the need for targeted antimicrobial therapy and prophylactic measures in high-risk patients.
    Pathological valve conditions disrupt the pressure gradients and forward flow required for efficient cardiac output, often leading to volume overload (regurgitation) or pressure overload (stenosis), both of which trigger maladaptive ventricular hypertrophy.
    The following table summarizes key pathological conditions, their etiologies, and their impact on hemodynamics:
    Feature Normal Valve Function Valvular Dysfunction (Examples) Physiological Consequences
    Pressure Gradient
    AO/PU valves: Open at LVP > AoP/PaP (120/25 mmHg); close at AoP/PaP > LVP.
    MV/TV valves: Open at LAP/RAP > LVP/RVP; close at LVP/RVP > LAP/RAP.
    • Aortic Stenosis: Reduced valve orifice increases LVP (200+ mmHg) to maintain flow, causing left ventricular hypertrophy (LVH) and myocardial ischemia.
    • Mitral Regurgitation: Incomplete coaptation allows backflow into LA (~50% of stroke volume), increasing LA pressure (30+ mmHg) and pulmonary congestion.
    • Stenosis: Leads to pressure overload, systolic dysfunction, and heart failure (e.g., aortic stenosis → syncope, angina, dyspnea).
    • Regurgitation: Causes volume overload, ventricular dilation, and reduced ejection fraction (EF <40%).
    Valve Leaflet Motion Smooth, synchronized opening/closing via chordae tendineae tension and ventricular-arterial pressure dynamics.
    • Mitral Valve Prolapse (MVP): Leaflet elongation causes mid-systolic click and regurgitation due to chordae rupture or myxomatous degeneration.
    • Tricuspid Stenosis: Fusion of leaflets (e.g., rheumatic heart disease) restricts RA→RV flow, increasing RA pressure (20+ mmHg) and systemic congestion.
    • MVP: May progress to arrhythmias (PVCs, AFib) or infective endocarditis.
    • Tricuspid Stenosis: Leads to hepatomegaly, ascites, and peripheral edema (right-sided failure).
    Condition Causes Effects on Hemodynamics
    Rheumatic Heart Disease (RHD)
    • Autoimmune response to Streptococcus pyogenes pharyngitis.
    • Chronic inflammation leading to fibrosis and commissural fusion.
    • Primarily affects mitral and aortic valves.
    • Mitral stenosis: Left atrial hypertension → pulmonary congestion, atrial fibrillation.
    • Aortic stenosis: Left ventricular pressure overload → concentric hypertrophy, reduced ejection fraction.
    • Regurgitation: Volume overload → ventricular dilation and heart failure.
    Calcific Aortic Stenosis (CAS)
    • Degenerative calcification of valve leaflets (age-related or associated with bicuspid aortic valve).
    • Systemic hypertension and dyslipidemia accelerate progression.
    • Severe pressure gradient across the aortic valve → left ventricular hypertrophy (LVH) and diastolic dysfunction.
    • Reduced cardiac output → syncope, angina, and congestive heart failure (classic triad).
    • Progression to pulmonary hypertension due to chronic afterload mismatch.
    Mitral Valve Prolapse (MVP)
    • Myxomatous degeneration of valve leaflets (genetic predisposition, connective tissue disorders).
    • Chordae tendineae elongation or rupture.
    • Mitral regurgitation: Volume overload → left atrial dilation, atrial fibrillation, and pulmonary edema.
    • Chronic regurgitation → eccentric hypertrophy and systolic dysfunction.
    • Asymptomatic in mild cases; severe cases may progress to heart failure with preserved ejection fraction (HFpEF).
    Infective Endocarditis (IE)
    • Bacterial (e.g., Staphylococcus aureus, Streptococcus viridans) or fungal colonization on damaged valves.
    • Risk factors: Prosthetic valves, intravenous drug use, congenital heart disease.
    • Valve destruction: Perforation, abscess formation, or leaflet vegetation → acute regurgitation or stenosis.
    • Embolization of vegetations → systemic sepsis, stroke, or myocardial abscess.
    • Right-sided IE in IV drug users → tricuspid regurgitation and pulmonary hypertension.
    Tricuspid Valve Dysfunction
    • Secondary to right ventricular pressure/volume overload (e.g., pulmonary hypertension, left-sided heart failure).
    • Carcinoid syndrome (serotonin-induced fibrosis).
    • Iatrogenic (e.g., pacemaker lead trauma).
    • Tricuspid regurgitation: Right atrial and ventricular dilation → hepatic congestion, ascites, and peripheral edema.
    • Chronic regurgitation → tricuspid annular dilation and worsening right heart failure.

    Symptoms Associated with Valvular Disorders

    The clinical presentation of valvular heart disease varies depending on the valve affected, the severity of dysfunction, and the compensatory capacity of the heart. Symptoms often emerge gradually, reflecting the progressive nature of hemodynamic derangements. Below, symptoms are categorized by the primarily affected valve, with an emphasis on acute vs. chronic manifestations and red flag indicators requiring urgent intervention.
    Early symptoms of valvular disease are frequently non-specific, delaying diagnosis until structural damage becomes irreversible. Dyspnea on exertion and fatigue are the most common initial complaints, while syncope or angina in aortic stenosis signal advanced disease.

    Aortic Valve Disorders

    Aortic stenosis and regurgitation primarily impair left ventricular performance, leading to symptoms of reduced cardiac output and forward flow obstruction.

    - Aortic Stenosis (AS)

  • Chronic AS:
  • Progressive exertional dyspnea (due to pulmonary congestion from left ventricular failure).
  • Angina pectoris (secondary to increased myocardial oxygen demand from LVH).
  • Presyncope/syncope (from reduced coronary perfusion during exertion).
  • Heart failure symptoms: Orthopnea, paroxysmal nocturnal dyspnea (PND), and peripheral edema.
  • Acute AS (e.g., post-procedural or endocarditis-related):
  • Pulmonary edema and cardiogenic shock due to abrupt pressure overload.

    • - Aortic Regurgitation (AR)

  • Chronic AR:
  • Wide pulse pressure (bounding pulses, "water-hammer" pulse).
  • Exertional dyspnea (from volume overload and diastolic dysfunction).
  • Fatigue and palpitations (due to increased stroke volume and tachycardia).
  • Acute AR (e.g., aortic dissection, endocarditis):
  • Pulmonary edema and hypotension from sudden volume overload.

    • ### Mitral Valve Disorders
    Mitral stenosis and regurgitation predominantly affect left atrial and ventricular filling, leading to pulmonary congestion and atrial arrhythmias.

    - Mitral Stenosis (MS)

  • Chronic MS:
  • Dyspnea on exertion (from elevated left atrial pressure → pulmonary edema).
  • Hemoptysis (ruptured pulmonary vessels).
  • Hoarseness (recurrent laryngeal nerve compression by enlarged left atrium).
  • Atrial fibrillation (due to atrial dilation and stretch-induced arrhythmogenesis).
  • Acute MS (e.g., rheumatic flare):
  • Pulmonary edema and acute right heart strain.

    • - Mitral Regurgitation (MR)

  • Chronic MR:
  • Fatigue and exertional dyspnea (from left ventricular

    • Diagnostic Methods and Imaging Techniques for Cardiac Valve Assessment

    Cardiac valve dysfunction, whether due to stenosis, regurgitation, or structural abnormalities, requires precise diagnostic evaluation to guide therapeutic decisions. Advanced imaging modalities enable detailed visualization of valve morphology, assessment of hemodynamic performance, and quantification of pathological flow disturbances. Echocardiography remains the cornerstone of valve assessment, supplemented by cardiac magnetic resonance imaging (MRI) and invasive techniques such as cardiac catheterization. These methods collectively provide complementary data on valve anatomy, functional dynamics, and the physiological impact of valvular disease.

    The integration of Doppler ultrasound principles into echocardiography enhances the ability to measure flow velocities, pressure gradients, and regurgitant volumes, offering objective metrics for disease severity. Cardiac MRI further refines volumetric and functional assessments, while catheterization remains essential for invasive pressure measurements and interventional procedures. Below, the procedural workflows and technical specifications for these diagnostic approaches are outlined, emphasizing their role in detecting and quantifying valvular abnormalities.

    Echocardiography in Valvular Disease Assessment

    Echocardiography, particularly transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE), is the primary non-invasive tool for evaluating cardiac valve structure and function. TTE provides a comprehensive assessment of valve morphology, leaflet motion, and associated hemodynamic changes, while TEE offers superior spatial resolution and is critical for pre-procedural planning in interventions such as valve repair or replacement. Doppler echocardiography further enables quantification of flow dynamics, including stenotic and regurgitant lesions.

    The interpretation of an echocardiogram for valvular abnormalities follows a structured approach, beginning with two-dimensional (2D) imaging to assess valve anatomy and leaflet integrity. Continuous-wave (CW) and pulsed-wave (PW) Doppler are then employed to measure flow velocities across the valve, while color Doppler visualizes abnormal flow patterns such as regurgitant jets or turbulent flow. Key metrics derived from these techniques include mean and peak pressure gradients, valve area calculations, and regurgitant volume/flow.

    Step-by-Step Echocardiographic Interpretation for Valvular Abnormalities

    The evaluation of a cardiac valve via echocardiography involves sequential steps to ensure accurate diagnosis and quantification of dysfunction. Below is a structured workflow for detecting and characterizing valvular abnormalities:
    1. 2D Echocardiographic Assessment
      • Examine valve leaflets for structural integrity, thickening, calcification, or vegetation.
      • Assess leaflet motion and coaptation to identify restricted movement (stenosis) or incomplete closure (regurgitation).
      • Measure valve orifice dimensions in multiple views (e.g., parasternal long-axis for aortic valve, apical four-chamber for mitral valve).
      • Evaluate surrounding structures (e.g., left ventricular size, wall motion abnormalities) that may influence valve function.
    2. Doppler Evaluation of Blood Flow Dynamics
      • Continuous-Wave (CW) Doppler
        Measures the highest velocity of blood flow across a valve, used primarily for assessing stenosis. The Bernoulli equation (ΔP = 4v²) converts velocity (v) to pressure gradient (ΔP), where v is in meters per second.
        • Position the sample volume across the valve orifice to obtain the maximum velocity envelope.
        • Record peak and mean gradients for quantitative assessment of stenosis severity.
      • Pulsed-Wave (PW) Doppler
        Used to measure flow velocities within the left ventricular outflow tract (LVOT) or across less turbulent valves, such as the mitral valve in diastole.
        • Align the sample volume with the direction of flow to obtain spectral Doppler traces.
        • Measure velocities at specific points (e.g., LVOT velocity for stroke volume calculations).
      • Color Doppler Imaging
        Visualizes abnormal flow patterns, including regurgitant jets, stenotic turbulence, and shunt flows. Jet area and direction correlate with regurgitation severity.
        • Adjust gain and scale to optimize jet visualization without aliasing.
        • Measure jet width at the vena contracta (narrowest point) for semi-quantitative assessment.
        • Assess jet area relative to left atrial or ventricular size for qualitative grading (e.g., mild, moderate, severe).
    3. Quantitative Assessment of Valve Function
      • Pressure Half-Time (PHT) for Mitral Stenosis
        The time required for the transmitral pressure gradient to fall by half, inversely correlated with mitral valve area (MVA). Normal PHT is <80 ms; values >150 ms suggest severe stenosis.
        • Measure PHT using PW Doppler across the mitral valve during diastole.
        • Calculate MVA using the continuity equation: MVA = 220 / PHT (cm²), adjusted for heart rate.
      • Effective Orifice Area (EOA) for Aortic Stenosis
        Derived from the continuity equation: EOA = (LVOT cross-sectional area × LVOT velocity-time integral) / (aortic velocity-time integral). Normal EOA > 3.0 cm²; severe stenosis < 1.0 cm².
        • Measure LVOT diameter (typically 1.8–2.2 cm) and velocity-time integral (VTI) via PW Doppler.
        • Obtain aortic valve VTI using CW Doppler and apply the continuity equation.
      • Regurgitant Volume and Fraction
        Quantified using the proximal isovelocity surface area (PISA) method or regurgitant jet area. Regurgitant volume >60 mL or fraction >50% indicates severe regurgitation.
        • PISA Method
          • Identify the hemispheric flow convergence zone proximal to the regurgitant orifice.
          • Measure the radius (R) of the isovelocity contour (typically 0.3–0.6 m/s) and aliasing velocity (V).
          • Calculate regurgitant volume (RV) = (2πR³ × V) / VTI and regurgitant fraction (RF) = RV / stroke volume.
        • Color Doppler Jet Area
          • Measure the regurgitant jet area at the vena contracta and compare to left atrial/ventricular area.
          • Use empirical ratios (e.g., jet area >40% of left atrium suggests severe mitral regurgitation).

    Cardiac Magnetic Resonance Imaging (MRI) in Valve Assessment

    Cardiac MRI provides superior soft-tissue contrast and volumetric accuracy, making it invaluable for assessing valve morphology, ventricular function, and flow dynamics without ionizing radiation. It is particularly useful for complex cases, such as congenital valve defects, prosthetic valve dysfunction, or multi-valvular disease. MRI techniques include cine MRI for functional assessment, phase-contrast MRI for flow quantification, and delayed enhancement for tissue characterization.

    Key advantages of cardiac MRI include:

  • High-resolution anatomical imaging of valve leaflets, chordae, and annuli.
  • Quantitative flow measurements using phase-contrast MRI to calculate regurgitant volume and forward stroke volume.
  • Tissue characterization via late gadolinium enhancement to identify fibrosis or inflammation in valve tissue.

    • For valvular stenosis, MRI-derived planar velocity mapping can measure peak and mean gradients, while 4D flow MRI provides comprehensive spatial and temporal flow data. In regurgitant lesions, through-plane flow encoding quantifies regurgitant volume with high precision, often serving as a reference standard for echocardiographic estimates.

    Cardiac Catheterization and Invasive Hemodynamics

    While non-invasive imaging dominates initial valve assessment, cardiac catheterization remains essential for direct pressure measurements, coronary angiography, and interventional procedures such as valvuloplasty or transcatheter valve replacement. Invasive techniques provide gold-standard data for pressure gradients, valve area calculations, and hemodynamic responses to interventions.

    Key procedures include:

  • Left Heart Catheterization: Measures aortic

    • what is the function of the cardiac valve - Ilustrasi 3

    Surgical and Interventional Treatments for Cardiac Valve Disorders

    Cardiac valve dysfunction, whether due to stenosis, regurgitation, or structural degeneration, often requires surgical or interventional correction to restore hemodynamic efficiency and prevent progressive heart failure. Traditional open-heart valve replacement remains the gold standard for severe valvular disease, but advancements in transcatheter technologies have expanded treatment options, particularly for high-risk or elderly patients. This section compares mechanical and bioprosthetic valve replacements with minimally invasive transcatheter alternatives (e.g., Transcatheter Aortic Valve Replacement (TAVR) and Mitral Clip), outlining their mechanisms, procedural risks, and patient selection criteria. Additionally, valvular repair techniques—such as annuloplasty and chordal replacement—are highlighted for their role in preserving native valve function, reducing complications associated with prosthetic implantation.

    Comparison of Valve Replacement Strategies: Mechanical vs. Bioprosthetic vs. Transcatheter Approaches

    Mechanical Valve Replacement
    Mechanical valves, typically constructed from pyrolytic carbon or titanium alloys, offer durability with near-lifetime functionality but require lifelong anticoagulation due to thrombogenic risks. The bileaflet design (e.g., St. Jude Medical, Edwards SAPIEN 3) minimizes gradients and regurgitation, while tilting-disc valves (e.g., Medtronic Hall) reduce thrombogenicity but may have higher turbulence. Indications include young patients (<60 years) with low bleeding risk, where anticoagulation compliance is feasible. Complications include structural failure (rare), hemolysis, and thromboembolism (incidence: ~0.5–1%/year despite warfarin). Patient suitability excludes those with contraindications to anticoagulants (e.g., history of GI bleeding, fall risk) or renal impairment.

    Bioprosthetic Valve Replacement
    Bioprosthetic valves, derived from bovine pericardium, porcine aortic roots, or equine pericardium, avoid anticoagulation but undergo structural degeneration over time (mean durability: 10–15 years for aortic, 7–10 years for mitral). Modern stentless valves (e.g., Freestyle) replicate native hemodynamics, reducing patient-prosthesis mismatch, while transcatheter bioprostheses (e.g., Edwards SAPIEN 3) are favored in elderly or frail patients. Complications include endocarditis (higher risk than mechanical valves), pannus formation, and nonstructural dysfunction (e.g., leaflet tear). Patient selection prioritizes individuals with high surgical risk or those unable to tolerate anticoagulation, though reoperation rates increase with time.

    Transcatheter Aortic Valve Replacement (TAVR)
    TAVR has revolutionized treatment for severe aortic stenosis (AS) in patients deemed inoperable or high-risk (STS score ≥8%). The procedure involves catheter-based deployment of a bioprosthesis (balloon-expandable: Edwards SAPIEN; self-expanding: Medtronic CoreValve) via transfemoral, transapical, or transaortic routes. Mechanism: The valve is crimped onto a delivery system, advanced to the native valve, and expanded to seat within the annulus, displacing calcified leaflets. Advantages include shorter recovery (median hospital stay: 3–5 days), reduced blood loss, and lower perioperative mortality (1.5–5% vs. 3–6% for SAVR). Risks include paravalvular leak (5–10%), vascular complications (5–10%), stroke (2–5%), and pacemaker implantation (10–20% for self-expanding valves). Patient suitability extends to octogenarians and those with porcelain aorta or chronic obstructive pulmonary disease (COPD), though younger patients (<75 years) may face structural valve deterioration within 10–15 years.

    Mitral Valve Repair and Transcatheter Edge-to-Edge Repair (Mitral Clip)
    For mitral regurgitation (MR), repair techniques (e.g., quadrangular resection, annuloplasty) preserve native valve function, reducing endocarditis risk and long-term anticoagulation needs. Annuloplasty rings (e.g., Carpentier-Edwards Physio II) restore annular geometry, while chordal replacement (Gore-Tex sutures) corrects prolapse. Transcatheter mitral clip (MitraClip, Abbott) approximates leaflet edges to reduce regurgitant orifice area, ideal for secondary MR or high surgical risk. Mechanism: Under transesophageal echocardiography (TEE) guidance, the clip is deployed via a femoral vein, grasping leaflet edges to create a double-orifice valve. Efficacy shows ≥2-grade MR reduction in 70–80% of patients, with 30-day mortality of ~5%. Complications include mitral stenosis (5–10%), leaflet perforation, and residual MR. Patient selection favors those with degenerative MR, functional MR (EF ≤30%), or prohibitive surgical risk.

    Preoperative Evaluation for Valvular Surgery: Echocardiographic Criteria and Risk Stratification

    A comprehensive preoperative assessment ensures optimal outcomes by evaluating valve pathology severity, operative risk, and comorbidities that may influence surgical strategy. The following structured workflow integrates echocardiographic parameters, societal risk scores, and comorbidity screening to guide decision-making.

    Echocardiographic Criteria for Surgical Intervention
    Echocardiography remains the cornerstone of valvular disease assessment, with specific thresholds dictating urgency and approach:

    - Aortic Stenosis (AS)

  • Severe AS: AVA ≤1.0 cm² (or ≤0.6 cm²/m²), mean gradient ≥40 mmHg, or peak velocity ≥4.0 m/s.
  • Low-flow, low-gradient AS: AVA ≤1.0 cm² with LVEF ≤50% and stroke volume index (SVI) <35 mL/m² (indicates contractile reserve testing with dobutamine stress echo).
  • Asymptomatic severe AS: AVA ≤0.6 cm² or rapid progression (ΔAVA <0.3 cm²/year) warrants consideration for TAVR in high-risk patients.

    • - Mitral Regurgitation (MR)

  • Severe MR: Effective regurgitant orifice (ERO) ≥0.40 cm², regurgitant volume ≥60 mL, or vena contracta ≥0.7 cm.
  • Functional MR: LVEF ≤60% with left atrial enlargement (LAVI >48 mL/m²) or pulmonary hypertension (PAP >50 mmHg).
  • Degenerative MR: Flail leaflet or bileaflet prolapse with symptoms (dyspnea, fatigue) or LV remodeling (LVESD >45 mm).

    • - Mitral Stenosis (MS)

  • Severe MS: MVA ≤1.5 cm², mean gradient ≥10 mmHg, or pressure half-time (PHT) >220 ms.
  • Symptomatic MS: NYHA Class II–IV despite medical therapy, with LA enlargement (LAVI >34 mL/m²) or pulmonary hypertension.

    • Risk Stratification Using Societal Scores
    Preoperative risk assessment employs validated scoring systems to predict 30-day mortality and guide surgical vs. transcatheter approaches:

    - Society of Thoracic Surgeons (STS) Score

  • Low risk: <2% mortality (ideal for SAVR).
  • Intermediate risk: 2–4% mortality (consider TAVR if comorbidities favor it).
  • High risk: ≥8% mortality (TAVR preferred for AS; mitral clip for MR).
  • EuroSCORE II
  • Additive model incorporating age, creatinine, ejection fraction, and comorbidities (e.g., COPD, diabetes).
  • Example: A 78-year-old with EF 40%, Cr 1.8 mg/dL, and prior CVA may have EuroSCORE II >10%, favoring TAVR.
  • Frailty Assessment
  • Gait speed <0.8 m/s, handgrip strength <20 kg, or unintentional weight loss increase delirium and mortality risk post-SAVR, making TAVR more suitable.

    • Comorb

    The cardiac valves embody the heart’s silent yet indispensable guardians, where anatomical precision meets physiological necessity. Their ability to adapt to pressure gradients, prevent regurgitation, and sustain unidirectional flow underscores their role as the linchpin of cardiovascular efficiency. Pathological deviations—whether from congenital malformations or degenerative diseases—highlight the fragility of this system, yet modern medicine offers corrective interventions ranging from minimally invasive transcatheter repairs to sophisticated valve replacements. As research continues to unravel the molecular underpinnings of valvular dysfunction, the clinical imperative remains clear: preserving valve integrity is not merely a treatment strategy but a cornerstone of long-term cardiac health and systemic well-being.

    FAQ

    What is the function of the cardiac valves?

    Cardiac valves ensure one-way blood flow through the heart by opening and closing in response to pressure changes. They prevent backflow (regurgitation) between chambers and into arteries, maintaining efficient circulation. The four main valves (tricuspid, pulmonary, mitral, aortic) coordinate to keep blood moving forward without mixing or leaking.

    What is the function of the heart valves?

    Heart valves regulate blood flow by allowing it to pass in only one direction through the chambers and into the major arteries. They open when pressure on one side is higher and close when pressure reverses, preventing backward flow. This coordination keeps oxygenated and deoxygenated blood separate and ensures the heart pumps effectively.

    What is the function of the aortic valve?

    The aortic valve controls blood flow from the left ventricle into the aorta, the body’s main artery, during ventricular systole (contraction). It closes immediately after ejection to prevent blood from flowing back into the ventricle, maintaining forward circulation to the systemic circuit. Dysfunction can cause conditions like aortic regurgitation or stenosis.

    What are the functions of the heart valves according to Quizlet-style definitions?

    Heart valves maintain unidirectional blood flow: the atrioventricular valves (tricuspid/mitral) allow blood from atria to ventricles but prevent backflow, while the semilunar valves (pulmonary/aortic) allow blood into arteries but close to stop regurgitation. Their opening/closing is pressure-dependent, ensuring efficient cardiac output and separation of oxygenated/deoxygenated blood.

    What is the function of the aortic valve as explained in Quizlet-style terms?

    The aortic valve is a semilunar valve that opens during ventricular systole to release blood into the aorta and closes during diastole to prevent backflow into the left ventricle. It ensures forward flow to the systemic circulation and maintains blood pressure by resisting reverse pressure. Stenosis or regurgitation disrupts this one-way mechanism.

    What are the functions of the heart valves and their supporting structures?

    Heart valves (leaflets/cusps) direct blood flow, while supporting structures like chordae tendineae (tethering AV valves), papillary muscles (preventing prolapse), and valve annuli (anchoring rings) stabilize their movement. The fibrous skeleton of the heart separates atrial/ventricular pathways and electrically insulates chambers. Dysfunction in these structures (e.g., ruptured chordae) leads to valve failure.